Abstract: Methods of treating a demyelinating disorder using inhibitors of the lymphotoxin pathway.

Abstract: Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.

Abstract: This invention relates to compositions and methods useful for activating LT-? receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-a and multiple subunits of lymphotoxin-?, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-? receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-? receptor which act as lymphotoxin-? receptor activating agents alone or in combination with other lymphotoxin-? receptor activating agents either in the presence or absence of lymphotoxin-a/? complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-? receptor antibodies either alone or in the presence of other lymphotoxin-? receptor activating agents to potentiate tumor cell cytotoxicity.

Abstract: This invention relates to compositions and methods useful for activating LT-? receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-? and multiple subunits of lymphotoxin-?, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-? receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-? receptor which act as lymphotoxin-? receptor activating agents alone or in combination with other lymphotoxin-? receptor activating agents either in the presence or absence of lymphotoxin-?/? complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-? receptor antibodies either alone or in the presence of other lymphotoxin-? receptor activating agents to potentiate tumor cell cytotoxicity.

Abstract: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.

Abstract: This invention relates to compositions and methods comprising “lymphotoxin-? receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.

Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

Abstract: This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-? receptor) activating agents where at least one LT-? receptor activating agent is an anti-LT-? receptor antibody.

Abstract: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.

Abstract: This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.

Abstract: The present invention provides PNF1, a novel isolated polypeptide, as well as a polynucleotide encoding PNF1 and antibodies that immunospecifically bind to PNF1 or any derivative, variant, mutant, or fragment of the PNF1 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the PNF1 polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.

Abstract: This invention relates to lymphotoxin-&bgr;, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-&bgr; and other peptides such as lymphotoxin-&agr; and to complexes comprising multiple subunits of lymphotoxin-&bgr;. These proteins and complexes are useful in holding LT-&agr; formed within the cell on the cell surface where the LT-&agr;/LT-&bgr; complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-&agr;/LT-&bgr; complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-&bgr;.

Abstract: Compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents” which block lymphotoxin-&bgr; receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

Abstract: This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-&bgr; receptor) activating agents where at least one LT-&bgr; receptor activating agent is an anti-LT-&bgr; receptor antibody.

Abstract: This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.

Abstract: This invention relates to compositions and methods useful for activating LT-&bgr; receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-&agr; and multiple subunits of lymphotoxin-&bgr;, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-&bgr; receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-&bgr; receptor which act as lymphotoxin-&bgr; receptor activating agents alone or in combination with other lymphotoxin-&bgr; receptor activating agents either in the presence or absence of lymphotoxin-&agr;/&bgr; complexes. A screening method for selecting such antibodies is provided.

Abstract: This invention relates to compositions and methods comprising "lymphotoxin-.beta. receptor blocking agents", which block lymphotoxin-.beta. receptor signalling. Lymphotoxin-.beta. receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-.beta. receptor extracellular domain that act as lymphotoxin-.beta. receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-.beta. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-.beta. receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-.beta. receptor signalling is provided.

Abstract: Human lipocortins III, IV, V and VI, DNA sequences and recombinant DNA molecules that are characterized in that they code for these human lipocortins. Hosts transformed with these sequences may be employed in the processes of this invention to produce the human lipocortin molecules of this invention. These polypeptides possess anti-inflammatory activity and are useful in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases.